Arterial thrombus formation in cardiovascular disease

Nature Reviews Cardiology

Volumn 8, Issue 9, 2011, Pages 502-512

  Lippi, Giuseppe ^a   Franchini, Massimo ^a   Targher, Giovanni ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CD36 ANTIGEN; FIBRIN; FIBRINOGEN; GLYCOPROTEIN VI; INTEGRIN; LIPOPROTEIN A; PHOSPHOLIPID ANTIBODY; RIVAROXABAN; THROMBIN; THROMBOPLASTIN; VERY LATE ACTIVATION ANTIGEN 2; VON WILLEBRAND FACTOR;

ARTERY THROMBOSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD CLOTTING; BLOOD FLOW VELOCITY; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; FIBRINOLYSIS; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; HYPERHOMOCYSTEINEMIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

ARTERIAL OCCLUSIVE DISEASES; BLOOD COAGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PLATELET ACTIVATION; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS;

EID: 80052102622     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.91     Document Type: Review

References (124)

1. Löwenberg, E. C., Meijers, J. C. & Levi, M. Platelet-vessel wall interaction in health and disease. Neth. J. Med. 65, 242-251 (2010).
2. Jerjes-Sanchez, C. Venous and arterial thrombosis: a continuous spectrum of the same disease? Eur. Heart J. 26, 3-4 (2005). (Pubitemid 40221115)
3. Franchini, M. & Mannucci, P. M. Venous and arterial thrombosis: different sides of the same coin? Eur. J. Intern. Med. 19, 476-481 (2008).
4. Lundberg, A. M. & Hansson, G. K. Innate immune signals in atherosclerosis. Clin. Immunol. 134, 5-24 (2010).
5. Andersson, J., Libby, P. & Hansson, G. K. Adaptive immunity and atherosclerosis. Clin. Immunol. 134, 33-46 (2010).
6. Libby, P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J. Lipid. Res. 50, S352-S357 (2009).
7. Furie, B. & Furie, B. C. Mechanisms of thrombus formation. N. Engl. J. Med. 359, 938-949 (2008).
8. WHO. World Health Statistics 2010 [online] http://www.who.int/whosis/ whostat/2010/en/index.html(2010).
9. Hodgkinson, C. P. & Ye, S. Toll-like receptors, their ligands, and atherosclerosis. Scientific World Journal 14, 437-453 (2011).
10. Badimon, J. J., Ibanez, B. & Cimmino, G. Genesis and dynamics of atherosclerotic lesions: implications for early detection. Cerebrovasc. Dis. 27, 38-47 (2009).
11. Penz, S. et al. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J. 19, 898-909 (2005). (Pubitemid 40827712)
12. Reininger, A. J. et al. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J. Am. Coll. Cardiol. 55, 1147-1158 (2010).
13. Mega, J. L. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374, 29-38 (2009).
14. Aird, W. C. Vascular bed-specific thrombosis. J. Thromb. Haemost. 5, 283-291 (2007). (Pubitemid 46958844)
15. Andrews, R. K., Gardiner, E. E., Shen, Y. & Berndt, M. C. Platelet interactions in thrombosis. IUBMB Life 56, 13-18 (2004). (Pubitemid 38209286)
16. Varga-Szabo, D., Pleines, I. & Nieswandt, B. Cell adhesion mechanisms in platelets. Arterioscler. Thromb. Vasc. Biol. 28, 403-412 (2008).
17. Massberg, S. et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J. Exp. Med. 197, 41-49 (2003). (Pubitemid 36110256)
18. -/- mice. Blood 111, 1266-1273 (2008). (Pubitemid 351213409)
19. Nergiz-Unal, R., Rademakers, T., Cosemans, J. M & Heemskerk, J. W. CD36 as a multiple-ligand signaling receptor in atherothrombosis. Cardiovasc. Hematol. Agents Med. Chem. 9, 42-55 (2011).
20. Ghosh, A. et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J. Clin. Invest. 118, 1934-1943 (2008). (Pubitemid 351632395)
21. Chen, K., Febbraio, M., Li, W. & Silverstein, R. L. A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein. Circ. Res. 102, 1512-1519 (2008).
22. Ofosu, F. A. Protease activated receptors 1 and 4 govern the responses of human platelets to thrombin. Transfus. Apher. Sci. 28, 265-268 (2003). (Pubitemid 36506501)
23. Sambrano, G. R., Weiss, E. J., Zheng, Y. W., Huang, W. & Coughlin, S. R. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413, 74-78 (2001). (Pubitemid 32843490)
24. Gupta, A., Williams, M. D., Macias, W. L., Molitoris, B. A. & Grinnell, B. W. Activated protein C and acute kidney injury: Selective targeting of PAR-1. Curr. Drug Targets 10, 1212-1226 (2009).
25. Yang, J. Xu, K. & Seiffert, D. Challenges and promises of developing thrombin receptor antagonists. Recent Pat. Cardiovasc. Drug Discov. 5, 162-170 (2010).
26. Falati, S., Gross, P., Merrill-Skoloff, G., Furie, B. C. & Furie, B. et al. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat. Med. 8, 1175-1181 (2002).
27. Lippi, G., Franchini, M. & Guidi, G. C. Diagnostic approach to inherited bleeding disorders. Clin. Chem. Lab. Med. 45, 2-12 (2007). (Pubitemid 46155552)
28. MacFarlane, R. G. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. Nature 202, 498-499 (1964).
29. Davie, E. W. & Ratnoff, O. D. Waterfall sequence for intrinsic blood clotting. Science 145, 1310-1312 (1964).
30. Monroe, D. M., Hoffman, M. & Roberts, H. R. Platelets and thrombin generation. Arterioscler. Thromb. Vasc. Biol. 22, 1381-1389 (2002).
31. Renné, T. et al. Defective thrombus formation in mice lacking coagulation factor XII. J. Exp. Med. 202, 271-281 (2005). (Pubitemid 41043823)
32. Stavrou, E. & Schmaier, A. H. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb. Res. 125, 210-215 (2010).
33. Gailani, D. & Renné, T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 27, 2507-2513 (2007). (Pubitemid 350158899)
34. Celi, A. et al. Thrombus formation: direct realtime observation and digital analysis of thrombus assembly in a living mouse by confocal and widefield intravital microscopy. J. Thromb. Haemost. 1, 60-68 (2003).
35. Furie, B. & Furie, B. C. In vivo thrombus formation. J. Thromb. Haemost. 5, 12-17 (2007).
36. Palabrica, T. et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P selectin on adherent platelets. Nature 359, 848-851 (1992).
37. Boden, G., Vaidyula, V., Homko, C., Mozzoli, M. & Rao, A. K. Differential effects of somatostatin on circulating tissue factor procoagulant activity and protein. Am. J. Physiol. Endocrinol. Metab. 292, E1333-E1339 (2007). (Pubitemid 46684602)
38. Marsik, C. et al. Polymorphism in the tissue factor region is associated with basal but not endotoxin-induced tissue factor-mRNA levels in leukocytes. J. Thromb. Haemost. 4, 745-749 (2006).
39. Sidelmann, J. J., Gram, J., Jespersen, J. & Kluft, C. Fibrin clot formation and lysis: basic mechanisms. Semin. Thromb. Hemost. 26, 605-618 (2000). (Pubitemid 32009600)
40. Bouma, B. N. & Mosnier, L. O. Thrombin activatable fibrinolysis inhibitor (TAFI)-how does thrombin regulate fibrinolysis? Ann. Med. 38, 378-388 (2006). (Pubitemid 44484876)
41. Muszbek, L., Bereczky, Z., Bagoly, Z., Shemirani, A. H. & Katona, E. Factor XIII and atherothrombotic diseases. Semin. Thromb. Hemost. 36, 18-33 (2010).
42. Muszbek, L., Bagoly, Z., Bereczky, Z. & Katona, E. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc. Hematol. Agents Med. Chem. 6, 190-205 (2008).
43. de Moerloose, P., Boehlen, F. & Neerman-Arbez, M. Fibrinogen and the risk of thrombosis. Semin. Thromb. Hemost. 36, 7-17 (2010).
44. von Hundelshausen, P. & Weber, C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ. Res. 100, 27-40 (2007). (Pubitemid 46066771)
45. Faber, D. R., de Groot, P. G. & Visseren, F. L. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes. Rev. 10, 554-563 (2009).
46. Targher, G., Zoppini, G., Moghetti, P. & Day, C. P. Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver. Semin. Thromb. Hemost. 36, 41-48 (2010).
47. Matsuda, S. et al. Human C-reactive protein enhances thrombus formation after neointimal balloon injury in transgenic rabbits. J. Thromb. Haemost. 9, 201-208 (2011).
48. Teupser, D. et al. No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J. Biol. Chem. 286, 6272-6279 (2011).
49. Koike, T. et al. Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation 120, 2088-2094 (2009).
50. Pepys, M. B., Baltz, M., Gomer, K., Davies, A. J. & Doenhoff, M. et al. Serum amyloid P component is an acute-phase reactant in the mouse. Nature 278, 259-261 (1979). (Pubitemid 9129075)
51. Reifenberg, K. et al. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? Arterioscler. Thromb. Vasc. Biol. 28, 1641-1646 (2005). (Pubitemid 41098934)
52. Liotta, L. A. et al. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 41, 4629-4636 (1981). (Pubitemid 12201384)
53. Mochan, E. & Keler, T. Plasmin degradation of cartilage proteoglycan. Biochim. Biophys. Acta. 800, 312-315 (1984). (Pubitemid 14033659)
54. Mackay, A. R., Corbitt, R. H., Hartzler, J. L. & Thorgeirsson, U. P. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res. 50, 5997-6001 (1990). (Pubitemid 20331412)
55. Zorio, E. et al. Fibrinolysis: the key to new pathogenetic mechanisms. Curr. Med. Chem. 15, 923-929 (2008). (Pubitemid 351736413)
56. Gebbink, M. F., Bouma, B., Maas, C. & Bouma, B. N. Physiological responses to protein aggregates: fibrinolysis, coagulation and inflammation (new roles for old factors). FEBS Lett. 583, 2691-2699 (2009).
57. Meltzer M. E., Doggen, C. J., de Groot, P. G., Rosendaal, F. R. & Lisman, T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin. Thromb. Hemost. 35, 468-477 (2009).
58. Ha, H., Oh, E. Y. & Lee, H. B. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat. Rev. Nephrol. 5, 203-211 (2009).
59. Franchini, M., Lippi, G., Manzato, F., Vescovi, P. P. & Targher, G. Hemostatic abnormalities in endocrine and metabolic disorders. Eur. J. Endocrinol. 162, 439-451 (2010).
60. Murata, M. et al. Genetic polymorphisms and risk of coronary artery disease. Semin. Thromb. Hemost. 24, 245-250 (1998). (Pubitemid 28345733)
61. Boekholdt, S. M. & Kramer, M. H. Arterial thrombosis and the role of thrombophilia. Semin. Thromb. Hemost. 33, 588-596 (2007). (Pubitemid 47429311)
62. Borecki, I. B. Contemporary approach to gene discovery: progress toward personalized medicine? Circ. Cardiovasc. Genet. 2, 1-2 (2009).
63. Kullo, I. J. & Cooper, L. T. Early identification of cardiovascular risk using genomics and proteomics. Nat. Rev. Cardiol. 7, 309-317 (2010).
64. Franchini, M., Peyvandi, F. & Mannucci, P. M. The genetic basis of coronary artery disease: from candidate genes to whole genomic analysis. Trends Cardiovasc. Med. 18, 157-162 (2008).
65. Voetsch, B. & Loscalzo, J. Genetic determinants of arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 24, 216-229 (2004). (Pubitemid 38197572)
66. Patay, B. A. & Topol, E. J. Is there a genetic basis for acute coronary syndrome? Nat. Clin. Pract. Cardiovasc. Med. 4, 596-597 (2007). (Pubitemid 350020367)
67. Parè G. et al. Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol. Am. J. Hum. Genet. 80, 673-682 (2007). (Pubitemid 46564404)
68. Morgan, T. M., Krumholz, H. M., Lifton, R. P. & Spertus, J. A. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 297, 1551-1561 (2007). (Pubitemid 46588368)
69. Song, Y., Stampfer M. J. & Liu, S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann. Intern. Med. 141, 137-147 (2004). (Pubitemid 38937836)
70. Ye, Z. et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 367, 651-658 (2006). (Pubitemid 43289155)
71. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 107, 1117-1122 (2003).
72. The International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
73. The International HapMap Consortium. The International HapMap Project. Nature 426, 789-796 (2003).
74. The International HapMap Consortium. A haplotype map of the human genome. Nature 437, 1299-1320 (2005).
75. Ding, K. & Kullo, I. J. Genome-wide association studies for atherosclerotic vascular disease and its risk factors. Circ. Cardiovasc. Genet. 2, 63-72 (2009).
76. Arking, D. E. & Chakravarti, A. Understanding cardiovascular disease through the lens of genome-wide association studies. Trends Genet. 25, 387-394 (2009).
77. Baudhuin, L. M. Genetics of coronary artery disease: focus on genome-wide association studies. Am. J. Transl. Res. 1, 221-234 (2009).
78. McCarthy, M. I. et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 9, 356-369 (2008). (Pubitemid 351556063)
79. Herrington, D. M. Cardiovascular genomics: outcome and implications. Can. J. Cardiol. 26, 60A-63A (2010).
80. Ozaki, K. et al. Functional SNPs in the lymphotoxin-α gene that are associated with susceptibility to myocardial infarction. Nat. Genet. 32, 650-654 (2002). (Pubitemid 35435179)
81. Ozaki, K. et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-α secretion in vitro. Nature 429, 72-75 (2004). (Pubitemid 38620552)
82. Ozaki, K. et al. SNPs in BRAP associated with risk of myocardial infarction in Asian populations. Nat. Genet. 41, 329-333 (2009).
83. Girelli, D., Martinelli, N., Peyvandi, F. & Olivieri, O. Genetic architecture of coronary artery disease in the genome-wide era: implications for the emerging "golden dozen" loci. Semin. Thromb. Hemost. 35, 671-682 (2009).
84. Helgadottir, A. et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316, 1491-1493 (2007). (Pubitemid 46906618)
85. Helgadottir, A. et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat. Genet. 40, 217-224 (2008). (Pubitemid 351171400)
86. McPherson, R. et al. A common allele on chromosome 9 associated with coronary heart disease. Science 316, 1488-1491 (2007). (Pubitemid 46906617)
87. Samani, N. J. et al. Genomewide association analysis of coronary artery disease. N. Engl. J. Med. 357, 443-453 (2007). (Pubitemid 47204873)
88. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
89. Shen, G. Q. et al. Association between four SNPs on chromosome 9p21 and myocardial infarction is replicated in an Italian population. J. Hum. Genet. 53, 144-150 (2008).
90. Larson, M. G. et al. Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med. Genet. 8, S5 (2007).
91. Broadbent, H. M. et al. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum. Mol. Genet. 17, 906-914 (2008)
92. The Myocardial Infarction Genetics Consortium. Genome wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat. Genet. 41, 334-341 (2009).
93. Erdmann, J. et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat. Genet. 41, 280-282 (2009).
94. Trégouët, D. A. et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat. Genet. 41, 283-285 (2009).
95. Lippi, G. & Guidi, G. Lipoprotein(a): an emerging cardiovascular risk factor. Crit. Rev. Clin. Lab. Sci. 40, 1-42 (2003). (Pubitemid 36250229)
96. Vokó, Z. Bereczky, Z., Katona, E., Adány, R. & Muszbek, L. Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis. Thromb. Haemost. 97, 458-463 (2007). (Pubitemid 46437809)
97. Laffan, M. A. Fibrinogen polymorphisms and disease. Eur. Heart J. 22, 2224-2226 (2001). (Pubitemid 34000975)
98. Gorog, D. A. Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease. J. Am. Coll. Cardiol. 55, 2701-2709 (2010).
99. Feinbloom, D. & Bauer, K. A. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler. Thromb. Vasc. Biol. 25, 2043-2053 (2005). (Pubitemid 41416299)
100. Ghaddar, H. M. et al. Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis. Circulation 98, 2815-2821 (1998). (Pubitemid 29003961)
101. Feng, D. et al. Factor VII gene polymorphism, factor VII levels, and prevalent cardiovascular disease: the Framingham Hear t Study. Ar terioscler. Thromb. Vasc. Biol. 20, 593-600 (2000). (Pubitemid 30086121)
102. Ridker, P. M. Hennekens, C. H., Schmitz, C., Stampfer, M. J. & Lindpaintner, K. et al. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 349, 385-388 (1997). (Pubitemid 27077666)
103. Herrmann, S. M. et al. The Leu33/Pro polymorphism (PlA1/PlA2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. Etude Cas-Temoins de l'Infarctus du Myocarde. Thromb. Haemost. 77, 1179-1181 (1997).
104. Ito, T., Ishida, F., Shimodaira, S. & Kitano, K. Polymorphisms of platelet membrane glycoprotein Ib alpha and plasma von Willebrand factor antigen in coronary artery disease. Int. J. Hematol. 70, 47-51 (1999).
105. Mercier, B. et al. Myocardial infarction: absence of association with VNTR polymorphism of platelet glycoprotein (GP) Ibα. Thromb. Haemost. 84, 921-922 (2000).
106. Ozelo, M. C. et al. Platelet glycoprotein Ibα polymorphisms modulate the risk for myocardia infarction. Thromb. Haemost. 92, 384-386 (2004). (Pubitemid 39172319)
107. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294, 1799-1809 (2005).
108. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375, 132-140 (2010).
109. Lühmann, D., Schramm, S. & Raspe, H. The role of homocysteine as a predictor for coronary heart disease. GMS Health. Technol. Assess. 3, Doc11 (2007).
110. Lippi, G. & Guidi, G. Lipoprotein(a): from ancestral benefit to modern pathogen? QJM 93, 75-84 (2000). (Pubitemid 30098769)
111. Kucharska-Newton, A. M. et al. Hemostasis, inflammation, and fatal and nonfatal coronary heart disease: long-term follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Arterioscler. Thromb. Vasc. Biol. 29, 2182-2190 (2009).
112. Miyakis, S. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4, 295-306 (2006).
113. Ben-Ami, D., Bar-Meir, E. & Shoenfeld, Y. Stenosis in antiphospholipid syndrome: a new finding with clinical implications. Lupus 15, 466-472 (2006). (Pubitemid 44147095)
114. Espinosa, G. & Cervera, R. Morbidity and mortality in the antiphospholipid syndrome. Curr. Opin. Pulm. Med. 15, 413-417 (2009).
115. Ridker, P. M., Hennekens, C. H., Lindpaintner, K., Stampfer, M. J. & Miletich, J. P. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 95, 59-62 (1997).
116. Wang, T. J. et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 355, 2631-2639 (2006). (Pubitemid 44969122)
117. Turpie, A. G. & Esmon, C. Venous and arterial thrombosis-pathogenesis and the rationale for anticoagulation. Thromb. Haemost. 105, 586-596 (2011).
118. Helgadottir, A. et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet. 36, 233-239 (2004). (Pubitemid 38282747)
119. Zwicker, J. I. et al. The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. Blood 108, 1280-1283 (2006). (Pubitemid 44232025)
120. Helgadottir, A. et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat. Genet. 38, 68-74 (2006). (Pubitemid 43011884)
121. Gudbjartsson, D. F. et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat. Genet. 41, 342-347 (2009).
122. Trégouët, D. A. et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat. Genet. 41, 283-285 (2009).
123. He, M. et al. Functional SNPs in HSPA1A gene predict risk of coronary heart disease. PLoS One 4, e4851 (2009).
124. Clarke, R. et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518-2528 (2009).